Oncology
Cancer
Malignancy
Neoplasm
Tumor
Benign tumor
Malignant tumor
Carcinoma
Sarcoma
Leukemia
Lymphoma
Myeloma
Melanoma
Glioma
Mesothelioma
Carcinogenesis
Oncogenesis
Tumorigenesis
Initiation
Promotion
Progression
Multistep carcinogenesis
Hallmarks of cancer
Sustaining proliferative signaling
Evading growth suppressors
Resisting cell death
Enabling replicative immortality
Inducing angiogenesis
Activating invasion and metastasis
Reprogramming energy metabolism
Evading immune destruction
Tumor-promoting inflammation
Genomic instability
Oncogene
Proto-oncogene
Tumor suppressor gene
DNA repair gene
Gatekeeper gene
Caretaker gene
RAS
MYC
EGFR
HER2
BRAF
p53
TP53
Retinoblastoma
RB
BRCA1
BRCA2
APC
PTEN
VHL
NF1
Mutation
Point mutation
Frameshift mutation
Missense mutation
Nonsense mutation
Deletion
Insertion
Amplification
Gene amplification
Translocation
Chromosomal translocation
Philadelphia chromosome
BCR-ABL
Fusion gene
Fusion protein
Copy number variation
Loss of heterozygosity
LOH
Microsatellite instability
MSI
MSI-high
MSI-low
Microsatellite stable
MSS
Mismatch repair
MMR
Deficient mismatch repair
dMMR
Proficient mismatch repair
pMMR
Epigenetic modification
DNA methylation
CpG island methylation
Histone modification
Chromatin remodeling
MicroRNA
miRNA
Long non-coding RNA
lncRNA
Cell cycle
G1 phase
S phase
G2 phase
M phase
Mitosis
Checkpoint
G1/S checkpoint
G2/M checkpoint
Spindle checkpoint
Cyclin
Cyclin-dependent kinase
CDK
CDK inhibitor
p16
p21
p27
Apoptosis
Programmed cell death
Intrinsic pathway
Extrinsic pathway
Caspase
Bcl-2 family
BAX
BCL-2
Autophagy
Necrosis
Senescence
Angiogenesis
Vascular endothelial growth factor
VEGF
Angiogenic switch
Hypoxia
Hypoxia-inducible factor
HIF
Invasion
Metastasis
Local invasion
Distant metastasis
Epithelial-mesenchymal transition
EMT
Mesenchymal-epithelial transition
MET
Cancer stem cell
Tumor microenvironment
Stromal cell
Cancer-associated fibroblast
CAF
Tumor-associated macrophage
TAM
Extracellular matrix
ECM
Matrix metalloproteinase
MMP
Metastatic cascade
Intravasation
Extravasation
Circulating tumor cell
CTC
Disseminated tumor cell
DTC
Metastatic niche
Seed and soil hypothesis
Common metastatic sites
Lymph node metastasis
Bone metastasis
Liver metastasis
Lung metastasis
Brain metastasis
Peritoneal metastasis
Warburg effect
Aerobic glycolysis
Metabolic reprogramming
Lactate production
Glucose transporter
GLUT
Immune evasion
Immune escape
Immune checkpoint
PD-1
PD-L1
CTLA-4
Regulatory T cell
Myeloid-derived suppressor cell
MDSC
Tumor-infiltrating lymphocyte
TIL
Tumor mutational burden
TMB
Neoantigen
Cancer risk factor
Carcinogen
Tobacco
Smoking
Alcohol
Obesity
Physical inactivity
Diet
Red meat
Processed meat
Ultraviolet radiation
UV radiation
Ionizing radiation
Radon
Asbestos
Benzene
Formaldehyde
Vinyl chloride
Arsenic
Aflatoxin
Hepatitis B virus
HBV
Hepatitis C virus
HCV
Human papillomavirus
HPV
Epstein-Barr virus
EBV
Human T-lymphotropic virus
HTLV
Helicobacter pylori
H. pylori
Inherited cancer syndrome
Hereditary cancer
Familial cancer
Li-Fraumeni syndrome
Lynch syndrome
Hereditary nonpolyposis colorectal cancer
HNPCC
Familial adenomatous polyposis
FAP
Hereditary breast and ovarian cancer syndrome
BRCA mutation
Cowden syndrome
PTEN hamartoma tumor syndrome
Von Hippel-Lindau disease
VHL
Neurofibromatosis
NF1
NF2
Tuberous sclerosis
Multiple endocrine neoplasia
MEN
MEN1
MEN2
Peutz-Jeghers syndrome
Juvenile polyposis syndrome
Hereditary diffuse gastric cancer
CDH1 mutation
Cancer screening
Screening test
Mammography
Mammogram
Breast cancer screening
Pap smear
Cervical cancer screening
HPV test
Colonoscopy
Colorectal cancer screening
Fecal occult blood test
FOBT
Fecal immunochemical test
FIT
Stool DNA test
Cologuard
Low-dose CT
Lung cancer screening
PSA
Prostate-specific antigen
Prostate cancer screening
Skin examination
Melanoma screening
Cancer diagnosis
Biopsy
Excisional biopsy
Incisional biopsy
Core needle biopsy
Fine needle aspiration
FNA
Endoscopic biopsy
Bronchoscopy
Colonoscopy
Cystoscopy
Histopathology
Cytology
Frozen section
Immunohistochemistry
IHC
Histologic grade
Tumor grade
Well-differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Gleason score
Nottingham grade
Scarff-Bloom-Richardson grade
Imaging
CT scan
Computed tomography
MRI
Magnetic resonance imaging
PET scan
Positron emission tomography
PET-CT
FDG-PET
Bone scan
Ultrasound
Mammography
Tumor marker
Biomarker
CEA
Carcinoembryonic antigen
CA 19-9
CA 125
AFP
Alpha-fetoprotein
PSA
Prostate-specific antigen
Beta-hCG
LDH
Lactate dehydrogenase
Cancer staging
Stage
TNM staging
T stage
Primary tumor
T1
T2
T3
T4
Tis
Carcinoma in situ
N stage
Lymph node
N0
N1
N2
N3
M stage
Metastasis
M0
M1
Stage 0
Stage I
Stage II
Stage III
Stage IV
AJCC staging
American Joint Committee on Cancer
FIGO staging
Federation of Gynecology and Obstetrics
Ann Arbor staging
Lugano classification
Rai staging
Binet staging
Performance status
ECOG performance status
Eastern Cooperative Oncology Group
PS 0
PS 1
PS 2
PS 3
PS 4
Karnofsky performance status
Cancer treatment
Curative intent
Palliative intent
Neoadjuvant therapy
Adjuvant therapy
Multimodal therapy
Combined modality therapy
Surgery
Surgical oncology
Resection
Tumor resection
Wide local excision
Mastectomy
Lumpectomy
Breast-conserving surgery
Prostatectomy
Radical prostatectomy
Nephrectomy
Colectomy
Gastrectomy
Pancreatectomy
Whipple procedure
Hepatectomy
Lung resection
Lobectomy
Pneumonectomy
Hysterectomy
Oophorectomy
Debulking surgery
Cytoreductive surgery
Lymph node dissection
Sentinel lymph node biopsy
SLNB
Margins
Surgical margin
Positive margin
Negative margin
Clear margin
R0 resection
R1 resection
R2 resection
Radiation therapy
Radiotherapy
External beam radiation therapy
EBRT
Intensity-modulated radiation therapy
IMRT
Image-guided radiation therapy
IGRT
Stereotactic body radiation therapy
SBRT
Stereotactic radiosurgery
SRS
Gamma Knife
CyberKnife
Proton therapy
Brachytherapy
Internal radiation therapy
High-dose-rate brachytherapy
HDR
Low-dose-rate brachytherapy
LDR
Radiation dose
Gray
Gy
Centigray
cGy
Fractionation
Hyperfractionation
Hypofractionation
Radiation field
Radiation oncology
Radiation side effects
Acute toxicity
Late toxicity
Radiation dermatitis
Radiation pneumonitis
Radiation fibrosis
Radiation enteritis
Chemotherapy
Cytotoxic chemotherapy
Systemic therapy
Chemotherapeutic agent
Alkylating agent
Cyclophosphamide
Ifosfamide
Temozolomide
Cisplatin
Carboplatin
Oxaliplatin
Antimetabolite
5-Fluorouracil
5-FU
Capecitabine
Gemcitabine
Methotrexate
Pemetrexed
Cytarabine
Anthracycline
Doxorubicin
Epirubicin
Idarubicin
Mitoxantrone
Topoisomerase inhibitor
Topotecan
Irinotecan
Etoposide
Antimicrotubule agent
Vinca alkaloid
Vincristine
Vinblastine
Vinorelbine
Taxane
Paclitaxel
Docetaxel
Cabazitaxel
Bleomycin
Actinomycin D
L-Asparaginase
Chemotherapy regimen
FOLFOX
FOLFIRI
FOLFIRINOX
AC
Adriamycin and Cyclophosphamide
TC
Docetaxel and Cyclophosphamide
CHOP
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
ABVD
Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
BEP
Bleomycin, Etoposide, Cisplatin
Chemotherapy administration
Intravenous
IV
Oral
Intrathecal
Intraperitoneal
Intra-arterial
Chemotherapy cycle
Treatment cycle
Dose-dense chemotherapy
Metronomic chemotherapy
Maintenance chemotherapy
Consolidation chemotherapy
Salvage chemotherapy
Chemotherapy side effects
Adverse effects
Toxicity
Bone marrow suppression
Myelosuppression
Neutropenia
Febrile neutropenia
Anemia
Thrombocytopenia
Nausea
Vomiting
Chemotherapy-induced nausea and vomiting
CINV
Antiemetic
Ondansetron
Granisetron
Aprepitant
Dexamethasone
Mucositis
Oral mucositis
Diarrhea
Constipation
Hair loss
Alopecia
Peripheral neuropathy
Chemotherapy-induced peripheral neuropathy
CIPN
Hand-foot syndrome
Palmar-plantar erythrodysesthesia
Cardiotoxicity
Cardiomyopathy
Nephrotoxicity
Hepatotoxicity
Pulmonary toxicity
Infertility
Fertility preservation
Secondary malignancy
Targeted therapy
Molecular targeted therapy
Monoclonal antibody
mAb
Rituximab
Trastuzumab
Herceptin
Pertuzumab
Bevacizumab
Avastin
Cetuximab
Panitumumab
Alemtuzumab
Daratumumab
Antibody-drug conjugate
ADC
Ado-trastuzumab emtansine
T-DM1
Brentuximab vedotin
Small molecule inhibitor
Tyrosine kinase inhibitor
TKI
Imatinib
Gleevec
Dasatinib
Nilotinib
Erlotinib
Gefitinib
Afatinib
Osimertinib
Crizotinib
Ceritinib
Alectinib
Lapatinib
Sunitinib
Sorafenib
Pazopanib
Axitinib
Cabozantinib
Lenvatinib
Regorafenib
Vemurafenib
Dabrafenib
Trametinib
Cobimetinib
mTOR inhibitor
Everolimus
Temsirolimus
CDK4/6 inhibitor
Palbociclib
Ribociclib
Abemaciclib
PARP inhibitor
Olaparib
Rucaparib
Niraparib
Talazoparib
Proteasome inhibitor
Bortezomib
Carfilzomib
Ixazomib
BCL-2 inhibitor
Venetoclax
Hedgehog pathway inhibitor
Vismodegib
Sonidegib
IDH inhibitor
Ivosidenib
Enasidenib
FLT3 inhibitor
Midostaurin
Gilteritinib
Resistance
Drug resistance
Primary resistance
Acquired resistance
Resistance mechanism
Target mutation
Bypass pathway
Immunotherapy
Cancer immunotherapy
Immune checkpoint inhibitor
Checkpoint inhibitor
Anti-PD-1
Pembrolizumab
Nivolumab
Cemiplimab
Anti-PD-L1
Atezolizumab
Durvalumab
Avelumab
Anti-CTLA-4
Ipilimumab
Combination immunotherapy
CAR T cell therapy
Chimeric antigen receptor
CAR T
Tisagenlecleucel
Axicabtagene ciloleucel
Adoptive cell transfer
Tumor-infiltrating lymphocyte therapy
TIL therapy
Cancer vaccine
Therapeutic vaccine
Preventive vaccine
HPV vaccine
Hepatitis B vaccine
Cytokine therapy
Interferon
Interferon-alpha
Interleukin-2
IL-2
Bacillus Calmette-Gu√©rin
BCG
Immune-related adverse event
irAE
Immune-related toxicity
Colitis
Hepatitis
Pneumonitis
Dermatitis
Endocrinopathy
Hypophysitis
Thyroiditis
Adrenal insufficiency
Type 1 diabetes
Hormone therapy
Endocrine therapy
Hormonal therapy
Anti-estrogen
Tamoxifen
Selective estrogen receptor modulator
SERM
Aromatase inhibitor
Letrozole
Anastrozole
Exemestane
Selective estrogen receptor degrader
SERD
Fulvestrant
Luteinizing hormone-releasing hormone agonist
LHRH agonist
GnRH agonist
Goserelin
Leuprolide
Antiandrogen
Bicalutamide
Enzalutamide
Apalutamide
Darolutamide
Abiraterone
Androgen deprivation therapy
ADT
Castration
Surgical castration
Medical castration
Hematopoietic stem cell transplant
HSCT
Bone marrow transplant
BMT
Stem cell transplant
Autologous transplant
Allogeneic transplant
Syngeneic transplant
Donor
Matched related donor
MRD
Matched unrelated donor
MUD
Haploidentical donor
Umbilical cord blood
Conditioning regimen
Myeloablative conditioning
Non-myeloablative conditioning
Reduced-intensity conditioning
RIC
Engraftment
Graft-versus-host disease
GVHD
Acute GVHD
Chronic GVHD
Graft-versus-tumor effect
GVT
Graft-versus-leukemia
GVL
Supportive care
Symptom management
Pain management
Antiemetics
Colony-stimulating factor
G-CSF
Filgrastim
Pegfilgrastim
GM-CSF
Erythropoiesis-stimulating agent
ESA
Epoetin alfa
Darbepoetin alfa
Transfusion
Blood transfusion
Platelet transfusion
Red blood cell transfusion
Bisphosphonate
Zoledronic acid
Denosumab
RANKL inhibitor
Tumor lysis syndrome
TLS
Hyperuricemia
Allopurinol
Rasburicase
Febrile neutropenia
Neutropenic fever
Antibiotic prophylaxis
Growth factor support
Cancer cachexia
Weight loss
Anorexia
Fatigue
Cancer-related fatigue
Cancer pain
Breakthrough pain
Neuropathic pain
Bone pain
Visceral pain
Opioid
Morphine
Oxycodone
Hydromorphone
Fentanyl
Palliative radiation
Palliative chemotherapy
Palliative care
Hospice care
End-of-life care
Response assessment
Treatment response
Complete response
CR
Partial response
PR
Stable disease
SD
Progressive disease
PD
Response Evaluation Criteria in Solid Tumors
RECIST
Target lesion
Non-target lesion
Progression-free survival
PFS
Overall survival
OS
Disease-free survival
DFS
Recurrence-free survival
RFS
Time to progression
TTP
Clinical trial
Phase I trial
Phase II trial
Phase III trial
Phase IV trial
Randomized controlled trial
RCT
Placebo
Blinding
Double-blind
Informed consent
Inclusion criteria
Exclusion criteria
Primary endpoint
Secondary endpoint
Surrogate endpoint
Intention-to-treat analysis
ITT
Per-protocol analysis
Kaplan-Meier curve
Hazard ratio
HR
Confidence interval
CI
P-value
Statistical significance
Specific cancers
Breast cancer
Invasive ductal carcinoma
IDC
Invasive lobular carcinoma
ILC
Ductal carcinoma in situ
DCIS
Lobular carcinoma in situ
LCIS
Triple-negative breast cancer
TNBC
ER-positive
PR-positive
HER2-positive
HER2-negative
Luminal A
Luminal B
Inflammatory breast cancer
Lung cancer
Non-small cell lung cancer
NSCLC
Small cell lung cancer
SCLC
Adenocarcinoma
Squamous cell carcinoma
Large cell carcinoma
EGFR mutation
ALK rearrangement
ROS1 rearrangement
KRAS mutation
Colorectal cancer
Colon cancer
Rectal cancer
Adenocarcinoma
Polyp
Adenomatous polyp
Serrated polyp
Lynch syndrome
Familial adenomatous polyposis
FAP
KRAS mutation
NRAS mutation
BRAF mutation
Microsatellite instability
MSI
Prostate cancer
Adenocarcinoma
Gleason score
PSA
Prostate-specific antigen
Active surveillance
Radical prostatectomy
Radiation therapy
Androgen deprivation therapy
Castration-resistant prostate cancer
CRPC
Ovarian cancer
Epithelial ovarian cancer
Serous carcinoma
Mucinous carcinoma
Endometrioid carcinoma
Clear cell carcinoma
Borderline ovarian tumor
Germ cell tumor
Sex cord-stromal tumor
CA-125
BRCA mutation
Pancreatic cancer
Pancreatic ductal adenocarcinoma
PDAC
Whipple procedure
KRAS mutation
TP53 mutation
CDKN2A
SMAD4
Liver cancer
Hepatocellular carcinoma
HCC
Cholangiocarcinoma
Bile duct cancer
Hepatitis B
Hepatitis C
Cirrhosis
Alpha-fetoprotein
AFP
Kidney cancer
Renal cell carcinoma
RCC
Clear cell RCC
Papillary RCC
Chromophobe RCC
VHL mutation
Bladder cancer
Urothelial carcinoma
Transitional cell carcinoma
Squamous cell carcinoma
Superficial bladder cancer
Muscle-invasive bladder cancer
Gastric cancer
Stomach cancer
Intestinal type
Diffuse type
HER2-positive
CDH1 mutation
Esophageal cancer
Adenocarcinoma
Squamous cell carcinoma
Barrett's esophagus
Thyroid cancer
Papillary thyroid cancer
Follicular thyroid cancer
Medullary thyroid cancer
Anaplastic thyroid cancer
BRAF mutation
RET rearrangement
Brain tumor
Glioblastoma
GBM
Glioblastoma multiforme
Astrocytoma
Oligodendroglioma
Ependymoma
Medulloblastoma
Meningioma
IDH mutation
MGMT methylation
Leukemia
Acute myeloid leukemia
AML
Acute lymphoblastic leukemia
ALL
Chronic myeloid leukemia
CML
Chronic lymphocytic leukemia
CLL
Myelodysplastic syndrome
MDS
Myeloproliferative neoplasm
MPN
Philadelphia chromosome
BCR-ABL
FLT3 mutation
NPM1 mutation
Lymphoma
Hodgkin lymphoma
Non-Hodgkin lymphoma
NHL
Diffuse large B-cell lymphoma
DLBCL
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Burkitt lymphoma
T-cell lymphoma
Cutaneous T-cell lymphoma
Mycosis fungoides
Multiple myeloma
Plasma cell myeloma
Monoclonal gammopathy
MGUS
Smoldering myeloma
M protein
Bence Jones protein
Lytic lesion
Melanoma
Malignant melanoma
Cutaneous melanoma
Superficial spreading melanoma
Nodular melanoma
Lentigo maligna melanoma
Acral lentiginous melanoma
Uveal melanoma
BRAF mutation
NRAS mutation
Breslow thickness
Clark level
Sentinel lymph node
Sarcoma
Soft tissue sarcoma
Bone sarcoma
Liposarcoma
Leiomyosarcoma
Rhabdomyosarcoma
Synovial sarcoma
Gastrointestinal stromal tumor
GIST
Osteosarcoma
Ewing sarcoma
Chondrosarcoma

